Anavex Life Sciences Corp (AVXL)

[polarbear77]

There’s that inflammation word again. You’re right Bourbon and great link Monarch.

Could reducing chronic inflammation also be part of the reason Dr Lisak believes a2-73 may promote remyelination in MS? (upstream approach, see my prior post)

Now an Alzheimer’s Disease inflammation article posted by monarch6500 today.

Anavex says about a2-73:

“The drug candidate has the potential to restore the molecular balance of cells by targeting misfolded proteins and mitochondria dysfunction. This ultimately prevents oxidative stress, inflammation, and cellular stress, processes that are shared by many neurological disorders and known to contribute for nerve cell degeneration.”

Another clue/benefit of our upstream approach in AD/PD/RS/MS etc?

Ironic as well that another tau protein removal wasted clearing drug had bad results reported this morning.

Are the regulators/scientific community/medical journalists taking note of this divergence in MOAs?